Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Pipeline Review, H2 2014

Published: Nov, 2014 | Pages: 49 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Pipeline Review, H2 2014', provides an overview of the Vancomycin Resistant Staphylococcus Aureus Infection (VRSA)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Vancomycin Resistant Staphylococcus Aureus Infection (VRSA), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Vancomycin Resistant Staphylococcus Aureus Infection (VRSA)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Vancomycin Resistant Staphylococcus Aureus Infection (VRSA)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) Overview 7
Therapeutics Development 8
Pipeline Products for Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Overview 8
Pipeline Products for Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Comparative Analysis 9
Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Therapeutics under Development by Companies 10
Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Therapeutics under Investigation by Universities/Institutes 11
Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Products under Development by Companies 14
Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Products under Investigation by Universities/Institutes 15
Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Companies Involved in Therapeutics Development 16
ContraFect Corporation 16
CrystalGenomics, Inc. 17
Debiopharm International S.A. 18
iNtRON Biotechnology Inc. 19
Wockhardt Limited 20
Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
CF-301 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
CG-400549 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Debio-1450 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Epidermicin-NI01 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
S-0111340 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
S-0111342 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
S-0111527 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
SAL-200 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecules to Activate Perforin-2 Synthesis for Bacterial Infections - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
SP-2078 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
WCK-4086 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Recent Pipeline Updates 43
Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Dormant Projects 46
Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Discontinued Products 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49

List of Tables
Number of Products under Development for Vancomycin Resistant Staphylococcus Aureus Infection (VRSA), H2 2014 8
Number of Products under Development for Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Number of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Pipeline by ContraFect Corporation, H2 2014 16
Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Pipeline by CrystalGenomics, Inc., H2 2014 17
Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Pipeline by Debiopharm International S.A., H2 2014 18
Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Pipeline by iNtRON Biotechnology Inc., H2 2014 19
Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Pipeline by Wockhardt Limited, H2 2014 20
Assessment by Monotherapy Products, H2 2014 21
Number of Products by Stage and Target, H2 2014 23
Number of Products by Stage and Mechanism of Action, H2 2014 25
Number of Products by Stage and Route of Administration, H2 2014 27
Number of Products by Stage and Molecule Type, H2 2014 29
Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) Therapeutics - Recent Pipeline Updates, H2 2014 43
Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Dormant Projects, H2 2014 46
Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) - Discontinued Products, H2 2014 47